Protein kinases, particularly those that interact with serine and threonine residues, are among the most promising drug targets due to their role in the development of diseases ranging from cancer and diabetes to neurodegenerative conditions.
The Flexyte technology, which will be launched at the 2010 Society for Biomolecular Sciences (SBS) meeting in Phoenix, US on April 11, uses “fluorescence lifetime” to measure activity of Protein kinase targets when they encounter drug candidates.
A company spokesman told Outsourcing-pharma that UK pharma major AstraZeneca, which began looking at Flexyte for drug discovery earlier this year , is continuing its assessment of the technology.